Dual Sexual and Drug-related Predictors of Hepatitis C Incidence among Sex Workers in a Canadian Setting: Gaps and Opportunities for Scale-up of Hepatitis C Virus Prevention, Treatment, and Care by Goldenberg, Shira M. et al.
International Journal of Infectious Diseases 55 (2017) 31–37Dual sexual and drug-related predictors of hepatitis C incidence among
sex workers in a Canadian setting: gaps and opportunities for scale-up
of hepatitis C virus prevention, treatment, and care
Shira M. Goldenberga,b,*, Julio Montanera,c, Melissa Braschela, Eugenia Sociasa,c,
Silvia Guillemia,c, Kate Shannona,c
aBritish Columbia Centre for Excellence in HIV/AIDS, St. Paul’s Hospital, 608–1081 Burrard Street, Vancouver, BC, V6Z 1Y6, Canada
b Faculty of Health Sciences, Simon Fraser University, Burnaby, BC, Canada
cDepartment of Medicine, University of British Columbia, St. Paul’s Hospital, Vancouver, BC, Canada
A R T I C L E I N F O
Article history:
Received 20 September 2016
Received in revised form 14 December 2016
Accepted 16 December 2016
Corresponding Editor: Eskild Petersen, Aar-
hus, Denmark
Keywords:
Hepatitis C
HIV
Sexually transmitted infections
Sex work
S U M M A R Y
Background: Hepatitis C virus (HCV) represents a significant cause of morbidity and mortality globally.
While sex workers may face elevated HCV risks through both drug and sexual pathways, incidence data
among sex workers are severely lacking. HCV incidence and predictors of HCV seroconversion among
women sex workers in Vancouver, BC were characterized in this study.
Methods: Questionnaire and serological data were drawn from a community-based cohort of women sex
workers (2010–2014). Kaplan–Meier methods and Cox regression were used to model HCV incidence and
predictors of time to HCV seroconversion.
Results: Among 759 sex workers, HCV prevalence was 42.7%. Among 292 baseline-seronegative sex
workers, HCV incidence density was 3.84/100 person-years (PY), with higher rates among women using
injection drugs (23.30/100 PY) and non-injection crack (6.27/100 PY), and those living with HIV (13.27/
100 PY) or acute sexually transmitted infections (STIs) (5.10/100 PY). In Cox analyses adjusted for
injection drug use, age (hazard ratio (HR) 0.94, 95% confidence interval (CI) 0.86–1.01), acute STI (HR 2.49,
95% CI 1.02–6.06), and non-injection crack use (HR 2.71, 95% CI 1.18–6.25) predicted time to HCV
seroconversion.
Discussion: While HCV incidence was highest among women who inject drugs, STIs and the use of non-
injection stimulants appear to be pathways to HCV infection, suggesting potential dual sexual/drug
transmission. Integrated HCV services within sexual health and HIV/STI programs are recommended.
© 2017 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
Contents lists available at ScienceDirect
International Journal of Infectious Diseases
journal home page: www.elsevier .com/ locat e/ i j idIntroduction
Hepatitis C virus (HCV) represents a significant and rising global
public health issue, with 185 million people estimated to be living
with HCV.1,2 Most persons living with HCV are chronically infected,
which poses a high risk for the development of liver cirrhosis, liver
cancer, and chronic liver disease.2 In May 2016, the first-ever global
hepatitis targets were adopted by the World Health Assembly,
galvanizing attention for this previously under-recognized and
relatively neglected health priority. These include reducing new
viral hepatitis infections by 90% and reducing deaths due to viral* Corresponding author. Tel.: +1 604 558 6678; fax: +1 604 806 9044.
E-mail address: gshi-sg@cfenet.ubc.ca (S.M. Goldenberg).
http://dx.doi.org/10.1016/j.ijid.2016.12.019
1201-9712/© 2017 The Authors. Published by Elsevier Ltd on behalf of International Soc
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).hepatitis by 65% by 2030, supporting increasing calls for scaling-up
access to HCV prevention, treatment, and care.3
HCV is known to disproportionately affect marginalized and
underserved populations, primarily people who inject drugs
(PWID),4–6 and to a lesser extent, men who have sex with men
(MSM).5,7 Although research on HCV among people who use non-
injection drugs has recently increased, little remains known
regarding HCV incidence among other key populations, particu-
larly sex workers, who face potentially elevated risks due to dual
drug and sexual transmission pathways. While little is known
about HCV among sex workers, this population faces a greatly
elevated burden of HIV, sexually transmitted infections (STIs), and
other sexual- and drug-related harms. These harms have been
primarily attributed to structural factors, including violence,
unsafe working conditions, stigma, and criminalization, whichiety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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well as access to health and harm reduction services.10,11
Among a small body of research on HCV among sex workers
from non-endemic settings such as Estonia,12 Argentina,13 and
South Korea,14 HCV prevalence has been found to be consistently
higher than in the general population, ranging from 1.4% among
sex workers in South Korea to 7.9% in Estonia. Although few studies
have assessed predictors of HCV incidence or prevalence among
sex workers, previous work suggests that sex workers who are
street-involved, criminalized, use drugs, and engage in syringe-
sharing are particularly vulnerable to HCV.15,16 Amidst global calls
for HCV treatment scale-up for key populations and the rising
availability of new and highly effective direct-acting antiviral
(DAA) treatments for HCV, addressing the gap in epidemiological
data regarding the incidence and prevalence of HCV among sex
workers remains of paramount importance.
In Metropolitan Vancouver, British Columbia (BC), women
sex workers face a disproportionate burden of HIV (with an
estimated prevalence of 12%),8,17 elevated sexual- and drug-related
harms,18,19 and structural barriers to HIV and harm reduction
services.8,10,11 Due to advances in HCV treatments, current efforts
to scale up HCV treatment are currently being explored in BC,
particularly for key populations facing intersecting harms related
to substance use disorders, HIV, and HCV. Given evidence
suggesting the potential for dual sexual and drug risk pathways
for HCV acquisition, particularly within the context of sex with
multiple partners, and the current dearth of HCV incidence data
among sex workers, this study aimed to characterize the incidence
and predictors of HCV infection among sex workers in Metropoli-
tan Vancouver, BC.
Methods
Data collection
Data were drawn from An Evaluation of Sex Workers’ Health
Access (AESHA), a prospective cohort of over 800 women sex
workers recruited through street, indoor, and online outreach
across Metropolitan Vancouver from January 2010 to August 2014.
AESHA is based on collaborations with sex work agencies that have
existed since 2005 and is monitored by a community advisory
board of more than 15 organizations. The study was approved by
the Providence Health Care/University of British Columbia
Research Ethics Board.
As used previously,17 eligibility criteria included self-identify-
ing as a woman (transgender male-to-female inclusive), age 14
years, exchanged sex for money within the last month, and
provided informed consent. The sample size was calculated to
detect associations between structural determinants of primary
interest (e.g., work environments, policing) and HIV/STI incidence.
Time–location sampling was used to recruit participants through
weekly outreach to street, indoor, and online venues across
Metropolitan Vancouver, which were identified through commu-
nity mapping and regularly updated. Between 10% and 15% of
individuals screened were deemed ineligible for the cohort. The
primary reason for ineligibility was not being actively engaged in
sex work at baseline (e.g., did not work within the last 30 days);
other reasons accounted for 5% of those screened as ineligible, and
included living outside the Metropolitan Vancouver area or being
unable to provide informed consent. Following an open cohort
design, participants continued to be actively recruited throughout
the life of the cohort through extensive ongoing outreach to street,
indoor, and online venues. The annual retention of participants
under active follow-up was >90%, and primary reasons for attrition
included mortality and migration outside Metropolitan Vancouver.
Extensive efforts were made to continue to follow women who hadmoved outside Metropolitan Vancouver during the study, includ-
ing mobile outreach/interview teams and phone interviews, to
support the high retention rates.
At baseline and semi-annually, participants completed inter-
viewer-administered questionnaires in English, Cantonese, or
Mandarin, alongside pre- and post-test counseling and voluntary
HIV, STI, and HCV testing; the interviewers were trained and
included both experiential (sex workers) and non-experiential
staff. The questionnaire collected detailed information on socio-
demographic characteristics, sex work patterns, sexual health,
substance use, occupational and lifetime violence, health and
social services access, and structural features of occupational and
residential environments. Participants completed study visits at
one of two storefront offices in Metropolitan Vancouver or at their
work/home location. All participants received $40 CAD at each visit
for their time, expertise, and travel.
Voluntary HIV, STI, and HCV testing and pre/post-test
counseling was performed by a project nurse. As per provincial
guidelines, HIV testing was performed using an ELISA, with
reactive tests followed by Western blot and individual RNA nucleic
acid amplification test (NAAT) testing where necessary. Urine
samples were collected to test for acute STIs including gonorrhea
and chlamydia using NAATs. Blood was drawn for syphilis, herpes
simplex virus 2 (HSV-2) antibody, and HCV antibody testing. Onsite
treatment was provided by the project nurse for symptomatic STIs,
and free STI and Papanicolaou testing was also offered, regardless
of study enrolment. Nurses offered referral and active connections
to care to HIV- and HCV-seropositive women not receiving care, as
well as education and referrals to other needed health and social
services.
Data analysis
Analyses were restricted to women who were HCV antibody-
negative at baseline and who had attended at least one follow-up
visit. Independent variables of interest were identified a priori and
included socio-demographic characteristics such as age and
indigenous ancestry. Time-updated variables used the last 6
months as a reference point and included HIV and acute STI
(defined as a new diagnosis of chlamydia, gonorrhea, or syphilis),
assessed based on serological and urine test results; sexual- and
drug-related risks, including condom negotiation and use (e.g.,
inconsistent condom use with clients) and drug use (e.g., non-
injection drug use, injection drug use, non-injection crack use);
and interactions with health and social services, assessed by asking
whether participants had experienced any barriers to accessing
healthcare or harm reduction services. Women previously diag-
nosed as HCV-seropositive were also asked several questions
regarding their access and uptake of HCV care, including whether
they had received regular blood tests for HCV, had seen an HCV
specialist, had been offered HCV treatment, and had been receiving
HCV treatment. Other time-updated variables included structural
exposures, including the participant’s primary place of soliciting
clients (coded as outdoor/public vs. indoor/independent), home-
lessness, client-perpetrated physical/sexual violence, and experi-
ences related to policing and criminalization, including
incarceration, police harassment, or arrest.
Kaplan–Meier analyses
Kaplan–Meier methods were used to estimate cumulative HCV
incidence. The date of HCV seroconversion was estimated as the
midpoint between the last negative and the first positive antibody
test result. Participants who remained persistently HCV-seroneg-
ative were right-censored at the time of their most recent available
HCV antibody test result. Time-zero for all prospective analyses
Figure 1. Kaplan–Meier cumulative HCV incidence among HCV-antibody negative
women sex workers (n = 292) in Metropolitan Vancouver, 2010–2014.
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rates were estimated for the full sample and stratified by risk
factors including recent injection drug use, non-injection crack
use, and co-infection with HIV or an STI at baseline.
Cox proportional hazards regression
The unadjusted and adjusted relative hazards of HCV serocon-
version were calculated using Cox proportional hazards regression.
Time-fixed variables included socio-demographic characteristics
such as age, duration of sex work, and indigenous ancestry; all
other variables (e.g., drug use, sexual behaviors, structural
exposures) were treated as time-updated covariates with occur-
rences in the prior 6 months, based on semi-annual follow-up data.
For the multivariable model, a fixed model was built that adjusted
for all variables described above that were statistically associated
with HCV seroconversion in unadjusted analyses. Given the
established role of injection drug use in HCV transmission,
multivariable analyses were adjusted for daily, less than daily, or
no injection drug use. A complete case analysis was performed,
where cases with missing observations were excluded from the
multivariable model. Analyses were conducted using SAS 9.4 (SAS
Institute, Cary, NC, USA); the threshold for statistical significance
was set at p < 0.05. All p-values are two-sided.
Results
HCV burden and participant characteristics
At baseline, 324 of 759 sex workers (42.7%) were HCV-
seropositive. The median age of participants was 34 years
(interquartile range (IQR) 28–42 years) and one-third (34.7%)
were of indigenous ancestry. A significantly higher prevalence of
HCV was observed among older and indigenous women, as well as
among women living with HIV or with acute STIs (Table 1). Women
who used drugs faced a disproportionately higher HCV burden; in
comparison to HCV-seronegative women, those who were HCV-
seropositive at baseline were significantly more likely to inject
drugs daily (42.0% vs. 6.2%) or less than daily (33.3% vs. 6.2%) and toTable 1
Descriptive statistics by baseline HCV prevalence among women sex workers in Metro
Variable HCV-seropositive 
(n = 324), n (%) 
Age, years (median, IQR) 36 (30–43) 
Canadian-born 299 (92.3%) 
Indigenous 160 (49.4%) 
HIV-seropositive 76 (23.5%) 
STI-seropositive 59 (18.2%) 
Duration of sex work, years (median, IQR) 16 (10–23) 
Inconsistent condom use (clients)a 73 (22.5%) 
Anal sex with clientsa 62 (19.1%) 
Any injection drug usea 244 (75.3%) 
Injection drug usea
Daily use 136 (42.0%) 
Less than daily use 108 (33.3%) 
No injection drug use 80 (24.7%) 
Any non-injection drug usea 302 (93.2%) 
Crack use
Non-injection crack usea 279 (86.1%) 
Injection crack usea 33 (10.2%) 
Primary place of solicitationa
Outdoor/public 251 (77.5%) 
Indoor/independent 73 (22.5%) 
Note: All data refer to n (%) of participants, unless specified otherwise. HCV, hepatitis 
a In the last 6 months.have used non-injection crack (86.1% vs. 39.5%) in the previous
6 months.
HCV incidence density and predictors of time to HCV seroconversion
At baseline, 292 women were HCV-antibody negative and had
attended at least one follow-up visit and were thus included in the
incidence analyses, contributing 1007 observations to the analysis
and over 52.5 months of follow-up.
During the observation period, 25 new HCV seroconversions
were identified, yielding an incidence density of 3.84/100 person-
years (PY) (95% confidence interval (CI) 2.58–5.71). The Kaplan–
Meier cumulative incidence after 52.5 months of follow-up was
11.9% (Figure 1). HCV incidence density was highest among women
who used injection drugs, at 23.30/100 PY (95% CI 13.88–39.12)politan Vancouver, 2010–2014 (N = 759).
HCV-seronegative Total
(n = 435), n (%) (N = 759), n (%)
33 (26–41) 34 (28–42)
234 (53.8%) 533 (70.2%)
103 (23.7%) 263 (34.7%)
7 (1.6%) 83 (10.9%)
26 (6.0%) 85 (11.2%)
4 (1–10) 9 (3–17)
66 (15.2%) 139 (18.3%)
40 (9.2%) 102 (13.4%)
54 (12.4%) 298 (39.3%)
27 (6.2%) 163 (21.5%)
27 (6.2%) 135 (17.8%)
381 (87.6%) 461 (60.7%)
211 (48.5%) 513 (67.6%)
172 (39.5%) 451 (59.4%)
7 (1.6%) 40 (5.3%)
149 (34.3%) 400 (52.7%)
286 (65.7%) 359 (47.3%)
C virus; IQR, interquartile range; STI, sexually transmitted infection.
Figure 2. Kaplan–Meier cumulative HCV incidence among HCV-antibody negative
women sex workers (n = 292) in Metropolitan Vancouver, 2010–2014, stratified by
injection drug use.
Figure 4. Kaplan–Meier cumulative HCV incidence among HCV-antibody negative
women sex workers (n = 292) in Metropolitan Vancouver, 2010–2014, stratified by
acute sexually transmitted infection (STI).
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used non-injection crack, at 6.27/100 PY (95% CI 3.98–9.86) (Figure
3). HCV incidence was also particularly high among women living
with HIV (13.27/100 PY, 95% CI 3.27–53.88) or who had an acute STI
(5.10/100 PY, 95% CI 1.31–19.83) (Figure 4).
In unadjusted Cox regression models, the relative hazard of HCV
seroconversion was higher among women who were younger
(hazard ratio (HR) 0.91/year, 95% CI 0.85–0.96), living with HIV (HR
3.71, 95% CI 0.91–15.10), had an acute STI (HR 6.93, 95% CI 2.84–
16.92) (Table 2), and used non-injection crack (HR 6.41, 95% CI
2.43–16.90). The hazard of HCV seroconversion was substantially
higher among sex workers who solicited clients in outdoor/public
spaces (HR 4.34, 95% CI 1.80–10.49), had experienced recent
homelessness (HR 4.14, 95% CI 1.91–9.00), and had faced structural
risks related to policing and criminalization, including recent
incarceration (HR 4.02, 95% CI 1.60–10.09).Figure 3. Kaplan–Meier cumulative HCV incidence among HCV-antibody negative
women sex workers (n = 292) in Metropolitan Vancouver, 2010–2014, stratified by
non-injection crack use.In a multivariable Cox proportional hazards regression model,
after adjustment for injection drug use, STI (HR 2.49, 95% CI 1.02–
6.06) and non-injection crack use (HR 2.71, 95% CI 1.18–6.25)
remained independent predictors of time to HCV seroconversion,
and younger age was a marginally significant predictor (HR 0.94,
95% CI 0.86–1.01; p = 0.10). In a multivariable Cox proportional
hazards regression model, after adjustment for injection drug use,
STI infection (HR: 2.49, 95%CI: 1.02-6.06),(HR 2.49, 95% CI 1.02–
6.06) and non-injection crack use (HR: 2.71, 95%CI: 1.18- 2.71, 95%
CI 1.18–6.25) remained independent predictors of time to HCV
seroconversion, : 0.94, 95%CI: 0.86-1.01; pand younger age was a
marginally significant predictor (HR 0.94, 95% CI 0.86–1.01; p =
0.10) (Table 3).
Discussion
In this 4.5-year study, after adjusting for injection drug use,
younger age, having an STI, and using non-injection crack were
independently associated with time to HCV seroconversion among
women sex workers in Metropolitan Vancouver, Canada. HCVTable 2
Bivariate Cox analysis of time to incident HCV infection among sex workers in
Metropolitan Vancouver, 2010–2014 (n = 292).
Variable HR 95% CI
Age, years 0.91 0.85–0.96
Indigenous 2.07 0.95–4.52
HIV-seropositive 3.71 0.91–15.10
STI-seropositive 6.93 2.84–16.92
Duration of sex work, years 1.01 0.98–1.04
Inconsistent condom use (clients)a 3.64 1.62–8.21
Anal sex with clientsa 1.34 0.41–4.38
Non-injection crack usea 6.41 2.43–16.90
Primarily solicits clients in outdoor/public spacesa 4.34 1.80–10.49
Homelessnessa 4.14 1.91–9.00
Client physical/sexual violencea 2.94 1.17–7.36
Incarcerationa 4.02 1.60–10.09
Police harassmenta 2.27 0.98–5.25
HCV, hepatitis C virus; HR, hazard ratio; CI, confidence interval; STI, sexually
transmitted infection.
a Time-updated measures using the last 6 months as a reference.
Table 3
Multivariable Cox analysis of time to incident HCV infection among sex workers in
Metropolitan Vancouver, 2010–2014 (n = 292)a.
Variable Adjusted HR 95% CI
Age, years 0.94 0.86–1.01
STI-seropositive 2.49 1.02–6.06
Non-injection crack useb 2.71 1.18–6.25
HCV, hepatitis C virus; HR, hazard ratio; CI, confidence interval; STI, sexually
transmitted infection.
a Results are adjusted for daily, less than daily, or no injection drug use in the last
6 months. Other variables that were considered, but not retained, in the final model
included client-perpetrated physical/sexual violence and incarceration in the last
6 months.
b Time-updated measures using the last 6 months as a reference.
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women who used injection drugs (23.30/100 PY) and was also
measurably higher among women using non-injection crack (6.27/
100 PY), as well as those living with HIV (13.27/100 PY). Although
studies with PWID have estimated HCV incidence to be between 20
and 40/100 PY,6 declining incidence has been demonstrated among
PWID in Vancouver and other settings characterized by the scale-
up of effective, community-based harm reduction programs.20,21
To the authors’ knowledge, this is the first study to examine HCV
incidence in a large cohort of sex workers, complementing the few
prior studies that have examined HCV prevalence among sex
workers elsewhere.12,22,23 In comparison to an estimated HCV
prevalence of 0.8–2.8% in the general Canadian population,24,25
43% of sex workers were HCV-seropositive. The disproportionate
HCV burden and relatively high incidence experienced by sex
workers in this context highlight the urgent imperative to scale up
tailored and targeted HCV prevention, treatment, and care for
marginalized women.
Whereas the sharing of drug paraphernalia and reuse of
syringes are the most commonly acknowledged routes of HCV
transmission, STIs and non-injection stimulant use also appeared
to be important pathways to HCV infection in this study,
suggesting the potential for dual sexual and drug-related
transmission among sex workers. Alongside drug-related risks,
studies have identified HIV and STI co-infections and sex with
multiple partners as risk factors for HCV acquisition, particularly
within high-income, low-prevalence settings.2,26,27 In the Wom-
en’s Interagency HIV Study, after adjusting for drug use, women
living with HIV were almost twice as likely to be HCV-
seropositive,28 an association primarily explained by sex with
male PWID. Among MSM, Canadian and European studies have
found sex worker involvement to be associated with HCV
seropositivity; for example, in a Canadian study, HCV-seropositiv-
ity was found to be associated with a gonorrhea diagnosis among
MSM with no history of injection drug use.7
In this study, non-injection crack use represented an important
predictor of HCV seroconversion among sex workers; although a
small proportion of women also reported using injected crack
(5.3%), the small number of events of injection crack use during
follow-up prevented its inclusion in the Cox analysis. Prior work
has demonstrated the potential for both drug-related and sexual
HCV transmission. Shared non-injection drug use paraphernalia
(e.g., mouthpieces, straws)29 and the use of inhaled and smoked
stimulants (e.g., crack, cocaine) have been associated with an
elevated HCV prevalence among substance-using and low-income
women,27 women at risk of or living with HIV in the USA,30 and
men and women who use drugs.31 Additionally, previous work has
shown that elevated sexual- and drug-related risks are often
experienced within the context of overlapping risks related to sex
work and crack use9,32; for example, associations have beenreported between HCV infection and non-injection (i.e., inhaled,
smoked) crack use, as well as sex work while using crack.32 In
Vancouver, it has previously been shown that stimulant use (e.g.,
crack, crystal meth) within the context of sex work relates to
broader patterns of poorer health outcomes and enhanced
structural vulnerabilities,18,19 including an enhanced risk of
violence, poor housing, police harassment, and reduced health
access.18 Importantly, previous work has suggested that gendered
dynamics may be linked to enhanced HCV-related vulnerability
among stimulant-using women, for whom sexual- and drug-
related risks are frequently experienced within the context of
intimate and paid relationships with substance-using male
partners.9,19,28,32 Although this body of evidence supports the
notion that the associations documented between STIs and non-
injection crack use in the present study may be attributable to
overlapping sexual and non-injection-related drug transmission of
HCV, it is also possible that these variables to some extent may
represent markers of a higher-risk population of sex workers,
rather than actual transmission pathways. Future studies with sex
workers and other populations that may be exposed to dual sexual
and drug-related risks are recommended to further explore these
transmission pathways across diverse settings.
Younger sex workers in this cohort also faced a trend towards
higher HCV incidence, pointing to gaps in harm reduction and HCV
prevention efforts for marginalized young women. In high-income
contexts such as the USA and Australia, HCV transmission is
disproportionately concentrated among young adults,2 and North
American studies indicate that street-involved youth who use
drugs are highly vulnerable to HCV.33,34 Importantly, the present
findings build on a prior study among drug-using youth in
Vancouver, which found that sex work involvement was associated
with HCV seroconversion for youth.15 These findings can be
contextualized by previous research involving marginalized
populations, including sex workers and people who use drugs,
which showed that youth often face a greater risk of blood-borne
infections and STIs due to the enhanced challenges faced
negotiating condom use and drug-related harms (frequently with
older partners), particularly within the context of recent sex work
or drug use initiation.17,33
Public health implications
In this study, while HCV incidence was highest among women
who inject drugs, sex workers with acute STIs and those who used
non-injection crack also faced a substantially increased risk of HCV
acquisition, highlighting the need to integrate HCV services with
sexual health and HIV/STI and substance use prevention and
treatment programs in this setting. The concerning trend of higher
HCV incidence among younger women underscores the need for
youth and sex worker-friendly HCV programming. These recom-
mendations are supported by the recently adopted global health
sector strategies for HIV, viral hepatitis, and STIs (2016–2021),
which include greater integration across HIV, STI, and viral
hepatitis prevention, treatment, and care, and a purposeful focus
on key populations, including sex workers. The pervasive barriers
sex workers face to HIV, sexual health, and harm reduction services
have been linked primarily to the enforcement of criminalized
legal approaches to sex work. For example, displacement due to
policing and the resulting lack of safe working and living
environments for sex workers often undermine access to HIV,
health, and harm reduction services.18 As such, structural
interventions, including the decriminalization of sex work, remain
critical to ensuring access to HIV, HCV, and harm reduction
programs.
The severe gaps in HCV testing and treatment faced by sex
workers in Vancouver have recently been demonstrated, with
36 S.M. Goldenberg et al. / International Journal of Infectious Diseases 55 (2017) 31–37fewer than half of HCV-positive women being connected to care
and almost none having received treatment.35 Despite the high
HCV prevalence and incidence among sex workers, most HCV-
related services target PWID, with a lack of sex worker-tailored or
women-centered models of care. While HCV treatment uptake has
been historically low for substance-using populations, new, highly
effective and tolerable HCV treatments represent an opportunity to
scale up voluntary and respectful treatment access. Importantly,
recent studies have demonstrated that marginalized and sub-
stance-using populations can achieve rates of virological response
comparable to the general population,4 with modeling also
suggesting that expanding harm reduction and HCV treatment
access to persons at increased risk for transmission has the
potential to reduce HCV incidence and prevalence in a cost-
effective manner.4
Conclusions
In this study, while HCV incidence was highest among sex
workers who injected drugs and women living with HIV, STIs and
non-injection stimulant crack use appear to be pathways to HCV
infection, suggesting potential dual sexual and drug-related
transmission of HCV. Altogether, the findings from this study
highlight the urgent need to integrate HCV services with sexual
health and HIV/STI addiction and harm reduction programs for
marginalized women. In light of the very high HCV prevalence and
incidence rates among sex workers and the recent availability of
highly effective and tolerable HCV treatment regimens, targeted,
community-based efforts to offer voluntary HCV prevention
(including prevention of re-infection), testing, treatment, and care
to sex workers should be a critical public health and human rights
priority.
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